03:48 PM EST - Valeant Pharmaceuticals International, Inc. : announced that its Bausch + Lomb subsidiary’s next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-centre, double-masked, vehicle-controlled, parallel-group study. Valeant Pharmaceuticals International, Inc.
shares V.VRX are trading up $2.34 at $144.00.
